Answer
Praxbind (idarucizumab) may be used during pregnancy if the expected clinical benefit outweighs the potential risks, although there are no data in pregnant women and reproductive and developmental toxicity studies have not been performed.
Sources for this answer
- Praxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 12Document updated
Sources checked